These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
547 related articles for article (PubMed ID: 15772701)
1. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Baron F; Maris MB; Storer BE; Sandmaier BM; Panse JP; Chauncey TR; Sorror M; Little MT; Maloney DG; Storb R; Heimfeld S Leukemia; 2005 May; 19(5):822-8. PubMed ID: 15772701 [TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
3. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation. Strober S Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036 [TBL] [Abstract][Full Text] [Related]
4. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival. Keil F; Prinz E; Moser K; Mannhalter C; Kalhs P; Worel N; Rabitsch W; Schulenburg A; Mitterbauer M; Greinix H Transplantation; 2003 Jul; 76(1):230-6. PubMed ID: 12865815 [TBL] [Abstract][Full Text] [Related]
5. CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies. O'Donnell PV; Jones RJ; Vogelsang GB; Seber A; Ambinder RF; Flinn I; Miller C; Marcellus DC; Griffin C; Abrams R; Braine HG; Grever M; Hess AD; Piantadosi S; Noga SJ Bone Marrow Transplant; 1998 Nov; 22(10):947-55. PubMed ID: 9849691 [TBL] [Abstract][Full Text] [Related]
6. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis. Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931 [TBL] [Abstract][Full Text] [Related]
7. Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation. Grosskreutz C; Ross V; Scigliano E; Fruchtman S; Isola L Biol Blood Marrow Transplant; 2003 Jul; 9(7):453-9. PubMed ID: 12869959 [TBL] [Abstract][Full Text] [Related]
8. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Maris MB; Sandmaier BM; Storer BE; Maloney DG; Shizuru JA; Agura E; Kliem C; Pulsipher M; Maziarz RT; McSweeney PA; Wade J; Langston AA; Chauncey TR; Bruno B; Blume KG; Storb R Biol Blood Marrow Transplant; 2006 Apr; 12(4):454-65. PubMed ID: 16545729 [TBL] [Abstract][Full Text] [Related]
9. Low T-cell chimerism is not followed by graft rejection after nonmyeloablative stem cell transplantation (NMSCT) with CD34-selected PBSC. Baron F; Baudoux E; Frère P; Tourqui S; Schaaf-Lafontaine N; Herens C; DePrijck B; Fillet G; Beguin Y Bone Marrow Transplant; 2003 Oct; 32(8):829-34. PubMed ID: 14520430 [TBL] [Abstract][Full Text] [Related]
10. Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day + 14 as a predictor of acute graft-versus-host disease. Petersen SL; Madsen HO; Ryder LP; Svejgaard A; Masmas TN; Dickmeiss E; Heilmann C; Vindeløv LL Biol Blood Marrow Transplant; 2004 May; 10(5):337-46. PubMed ID: 15111933 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Panse JP; Heimfeld S; Guthrie KA; Maris MB; Maloney DG; Baril BB; Little MT; Chauncey TR; Storer BE; Storb R; Sandmaier BM Br J Haematol; 2005 Mar; 128(5):659-67. PubMed ID: 15725088 [TBL] [Abstract][Full Text] [Related]
12. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Baron F; Baker JE; Storb R; Gooley TA; Sandmaier BM; Maris MB; Maloney DG; Heimfeld S; Oparin D; Zellmer E; Radich JP; Grumet FC; Blume KG; Chauncey TR; Little MT Blood; 2004 Oct; 104(8):2254-62. PubMed ID: 15226174 [TBL] [Abstract][Full Text] [Related]
13. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907 [TBL] [Abstract][Full Text] [Related]
15. Rapid hematopoietic engraftment following fractionated TBI conditioning and transplantation with CD34(+) enriched hematopoietic progenitor cells from partially mismatched related donors. Redei I; Langston AA; Lonial S; Cherry JK; Allen AJ; Hamilton E; Jones M; Bartlett VM; Waller EK Bone Marrow Transplant; 2002 Sep; 30(6):335-40. PubMed ID: 12235516 [TBL] [Abstract][Full Text] [Related]
16. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults. Peterlin P; Delaunay J; Guillaume T; Gastinne T; Mahé B; Dubruille V; Blin N; Le Bourgeois A; Brissot E; Lodé L; Le Gouill S; Moreau P; Mohty M; Chevallier P Biol Blood Marrow Transplant; 2015 Jan; 21(1):180-4. PubMed ID: 25175796 [TBL] [Abstract][Full Text] [Related]
17. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568 [TBL] [Abstract][Full Text] [Related]
18. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors. Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376 [TBL] [Abstract][Full Text] [Related]
19. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Zaucha JM; Gooley T; Bensinger WI; Heimfeld S; Chauncey TR; Zaucha R; Martin PJ; Flowers ME; Storek J; Georges G; Storb R; Torok-Storb B Blood; 2001 Dec; 98(12):3221-7. PubMed ID: 11719357 [TBL] [Abstract][Full Text] [Related]
20. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Bensinger WI; Buckner CD; Shannon-Dorcy K; Rowley S; Appelbaum FR; Benyunes M; Clift R; Martin P; Demirer T; Storb R; Lee M; Schiller G Blood; 1996 Dec; 88(11):4132-8. PubMed ID: 8943847 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]